Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Before you fill a prescription for Dupixent, your ENT specialist wants you to understand that this medication is a powerful immunosuppressant that works differently from traditional allergy treatments—and it comes with a price tag and commitment that deserve careful consideration. Dupixent (dupilumab) represents a significant shift in how ENTs approach chronic sinus and nasal conditions, particularly after the FDA’s February 2026 approval for Allergic Fungal Rhinosinusitis (AFRS), making it the first and only medication approved for this condition in patients 6 years and older with a history of sinus surgery. If you’re considering Dupixent, your doctor wants you to know the real efficacy data, the actual side effects you might experience, the genuine costs involved, and whether this medication is truly the right fit for your specific situation.
The enthusiasm around Dupixent in the ENT community is rooted in concrete trial results. In the LIBERTY-AFRS-AIMS trial, 62 patients who received Dupixent for 52 weeks showed a 92% reduction in their need for future sinus surgery or systemic corticosteroid use compared to placebo—a remarkable outcome for a condition that typically requires repeated surgical interventions. However, this doesn’t mean Dupixent is universally appropriate, instantly effective, or without significant considerations that your doctor will want to discuss with you upfront.
Table of Contents
- What Conditions Is Dupixent Actually FDA-Approved For?
- How Well Does Dupixent Work in the Patients Who Need It?
- What Side Effects Does Dupixent Actually Cause?
- What Does Dupixent Actually Cost in 2026?
- Is Dupixent the Right Choice for Your Specific Situation?
- How Does Dupixent Compare to Alternative Treatments?
- What’s Coming Next for Dupixent and How Might It Affect Your Decision?
- Conclusion
What Conditions Is Dupixent Actually FDA-Approved For?
Dupixent currently has nine approved indications globally, serving more than 1.4 million patients worldwide. For ENTs specifically, the approved uses include moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP), the newly approved Allergic Fungal Rhinosinusitis, and chronic rhinosinusitis without nasal polyps. The condition-specific approvals matter because Dupixent works on a specific inflammatory pathway—it blocks interleukin-4 receptor alpha (IL-4Rα)—which makes it highly effective for Type 2 inflammatory conditions but irrelevant for infections, structural issues, or other causes of sinus problems. The AFRS approval is particularly significant because this condition has historically been difficult to manage.
AFRS occurs when fungi trigger an allergic reaction in the sinuses, typically requiring multiple surgeries and aggressive treatment. Patients with AFRS have often had surgery repeatedly, only to see the condition return within months. The Dupixent data showed that among patients receiving the medication, the need for future sinus surgery or systemic corticosteroid therapy was dramatically reduced—this is the practical benefit ENTs emphasize when they recommend the drug. However, your ENT will want to confirm that you actually have one of these specific conditions through imaging and testing before prescribing Dupixent. If your sinus issues stem from structural abnormalities, untreated dental problems, or bacterial infections, Dupixent won’t help—and taking it would simply expose you to side effects and cost without benefit.
How Well Does Dupixent Work in the Patients Who Need It?
For chronic rhinosinusitis with nasal polyps specifically, research indicates that Dupixent may be as effective as or more effective than mepolizumab (another biologic used for nasal polyps) in patients who have already had sinus surgery. A head-to-head comparison study between these two medications is expected to complete in 2026, which will provide direct evidence that ENTs are waiting for. What we know now is that Dupixent tends to work relatively quickly—many patients report improvement in symptoms like nasal congestion and loss of smell within weeks, though full benefits can take 3-4 months. The LIBERTY-AFRS-AIMS trial, which provides the strongest evidence for Dupixent’s effectiveness, tracked 62 patients (33 on Dupixent, 29 on placebo) over a full year.
The primary outcome—no need for sinus surgery or systemic corticosteroids during the treatment period—was met by significantly more Dupixent patients. This is important because it shifts the conversation from “Does Dupixent reduce symptoms?” to “Does Dupixent prevent the escalation of treatment that would otherwise require surgery or powerful oral steroids?” For patients with AFRS who face surgery every 12-18 months, this represents a genuine quality-of-life improvement and reduced healthcare burden. That said, “effective” doesn’t mean “universally effective.” Some patients respond dramatically to Dupixent within weeks, while others show only modest improvement or no improvement at all. Your ENT cannot predict in advance who will be a strong responder—this typically requires a trial period of at least 4 months before deciding whether the medication is working for you specifically. If you don’t respond well, Dupixent won’t prevent you from needing surgery anyway, and you’ll have paid for months of treatment that didn’t help.
What Side Effects Does Dupixent Actually Cause?
The side effects profile for Dupixent in the AFRS trial showed that 15% of patients on Dupixent developed COVID-19 compared to 14% on placebo, and 12% experienced nosebleeds on Dupixent compared to 4% on placebo. These numbers reflect the medication’s immunosuppressive action—by modulating immune response, Dupixent increases vulnerability to infections and can affect normal tissue integrity in the nose. Beyond the trial-specific data, common side effects reported across all approved Dupixent indications include injection site reactions (redness, swelling, itching at the injection site), elevated eosinophil counts in the blood, insomnia, toothache, gastritis, and joint pain. More serious but less common side effects deserve attention before you start treatment. Eye problems—including keratitis, conjunctivitis, and sometimes vision changes—have been reported and are significant enough that your ophthalmologist should be aware you’re taking Dupixent. Severe allergic reactions, though rare, can occur.
Additionally, because Dupixent suppresses certain immune pathways, there’s an increased risk of parasitic infections in people living in or traveling to areas where these infections are common. Your ENT will want to screen for these risk factors before starting you on the medication. The injection site reactions deserve specific mention because they affect quality of life in ways that clinical trials sometimes understate. Dupixent is a self-injected medication given subcutaneously every two weeks. Some patients experience minimal reaction, while others develop persistent itching, redness, or swelling at injection sites. Rotating injection sites and using proper technique helps, but some patients find this a genuine barrier to long-term compliance.
What Does Dupixent Actually Cost in 2026?
This is where the conversation becomes most critical and most difficult. The list price for Dupixent is $4,193.03 USD per carton, but real-world prices at retail pharmacies frequently exceed $5,500. Without any insurance assistance, you’re looking at approximately $3,500–$4,000 per month—and this is an ongoing cost, not a one-time expense. For someone without insurance or with a high deductible plan, this represents thousands of dollars annually that may not be feasible to spend on a medication that hasn’t yet proven effective for them personally. Insurance coverage does reduce this burden significantly.
The Dupixent MyWay Card allows 68% of insured patients to pay $0–$100 per month, making the medication accessible to most people with employer or marketplace insurance. Medicare Part D coverage in 2026 includes a maximum out-of-pocket drug cost cap of $2,100 annually, which creates a ceiling on what you’d pay if you’re on Medicare. For uninsured patients who meet income and residency requirements, Sanofi offers a Patient Assistance Program that can reduce or eliminate the cost entirely. However, your ENT wants you to understand the total financial commitment before starting. You’ll need to verify your insurance coverage, understand whether there’s a deductible or copay, confirm how long you might need to take the medication (potentially indefinitely), and have a realistic conversation about what happens if your insurance coverage changes. Additionally, if you’re part of a health plan with step therapy requirements, you may need to try and fail other treatments before insurance will cover Dupixent.
Is Dupixent the Right Choice for Your Specific Situation?
Your ENT will consider whether you’re a good candidate by evaluating several factors. Dupixent works best in patients with confirmed Type 2 inflammation—meaning testing shows elevated eosinophils or specific inflammatory markers. It’s approved for adults and children 6 years and older, but the dosing differs by age and weight. Patients who have already had sinus surgery tend to be better candidates because they’ve exhausted more conservative options and are at risk of recurrent surgery without additional intervention. Dupixent is not appropriate if you have an active infection, including active COVID-19 or tuberculosis, or if you’re allergic to dupilumab or any ingredient in the formulation. If you have immunodeficiency disorders or are severely immunocompromised, your ENT will carefully weigh the risks.
Patients taking live vaccines need to complete their vaccination series before starting Dupixent, and you won’t be able to receive live vaccines while on the medication. If you’re planning pregnancy or are currently pregnant, this conversation becomes more complex, as the long-term safety data in pregnancy is still limited. The most critical factor your ENT wants you to understand is that Dupixent works best for patients with realistic expectations. It’s not a cure—it’s a maintenance therapy that reduces inflammation and prevents disease progression. You might still need occasional sinus infections treated, occasional nasal steroids for flare-ups, and possibly surgery if new issues arise despite treatment. The goal is to reduce how often these events occur and how severe they become.
How Does Dupixent Compare to Alternative Treatments?
If you have chronic rhinosinusitis with nasal polyps, your alternative treatment options include saline irrigations, topical nasal steroids (like mometasone or fluticasone), systemic corticosteroids (oral prednisone for acute exacerbations), and other biologics like mepolizumab or reslizumab. Nasal steroids are significantly cheaper, have fewer systemic side effects, and work adequately for mild-to-moderate disease. However, they lose effectiveness over time and don’t work for everyone. Systemic corticosteroids are effective but carry serious side effects with long-term use, including bone loss, weight gain, and increased infection risk—which is precisely why ENTs want to move patients off systemic steroids and onto biologics like Dupixent. For AFRS specifically, the comparison is more straightforward because Dupixent is now the only FDA-approved medication for this condition.
Previously, AFRS patients were managed with repeated surgery and systemic corticosteroids or antifungal medications. The Dupixent approval represents a genuine advance for this population because it provides a non-surgical alternative that actually prevents disease recurrence. The comparison between Dupixent and mepolizumab for nasal polyps is becoming increasingly important as more biologics enter the market. Both drugs are effective, but Dupixent appears to have a broader effect on the inflammatory cascade. Mepolizumab is specifically targeted at eosinophil reduction, while Dupixent works upstream by blocking IL-4 receptor signaling. The 2026 head-to-head trial will provide the definitive answer about which works better for which patients.
What’s Coming Next for Dupixent and How Might It Affect Your Decision?
Sanofi and Regeneron are actively developing next-generation formulations that could change how Dupixent is delivered and dosed. A quarterly (Q4W) dosing co-formulation is entering studies in the second half of 2026, which would mean moving from bi-weekly injections to once-monthly injections. For patients who struggle with compliance or find injections burdensome, this represents a genuine improvement in convenience. Higher-dose formulations for severe asthma are also in development, though these are less relevant for ENT-specific conditions.
The market data shows that Dupixent sales reached €4.2 billion in Q1 2026 alone, representing 31% growth year-over-year. This financial success is driving continued research and development, which typically leads to better formulations, expanded indications, and potentially improved pricing through competition if other companies develop similar medications. For now, Dupixent remains the only medication in its class for AFRS and one of the few options for severe nasal polyposis, but this landscape may change in the coming years. Your ENT’s perspective on Dupixent is informed by watching this medication’s real-world performance in patients over the past several years. The data is increasingly positive, but it’s always evolving as more patients use the medication long-term and more comparative data emerges.
Conclusion
What ENTs want you to know before buying Dupixent boils down to this: It’s a genuinely effective medication for specific Type 2 inflammatory sinus conditions, with trial data proving it can prevent the need for surgery and systemic corticosteroids in many patients. However, it’s expensive even with insurance, it requires long-term commitment, it carries real side effects including increased infection risk, and it doesn’t work for everyone. Before starting Dupixent, you need clear confirmation that you have a condition it’s actually approved for, an understanding of what it will cost you personally, realistic expectations about what improvement looks like, and honest conversation with your ENT about whether the benefits outweigh the risks and costs for your specific situation.
The decision to use Dupixent should be collaborative between you and your healthcare team. Bring your insurance information, discuss your previous treatments and why they didn’t work, ask directly about the timeline for assessing whether it’s helping, confirm the injection technique and site rotation to minimize reactions, and establish a clear endpoint for evaluation—typically 4 months is reasonable to determine if the medication is working well enough to continue. Your ENT wants you to be informed, protected from preventable side effects, and genuinely improved by this medication rather than simply taking it because it’s the newest option available.
